Stock A237690 ST PHARM CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ST Pharm Co.,Ltd.

Equities

A237690

KR7237690003

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 28/06/2024 am IST 		5-day change 1st Jan Change
85,500 KRW -1.61% Intraday chart for ST Pharm Co.,Ltd. -7.87% +26.11%
2023 ST Pharm Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
2021 ST Pharm Co.,Ltd. Announces Expansion of Oligonucleotide Facility CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 5,55,949 19,36,493 25,96,915 16,47,649 12,75,235 16,64,131 - -
Enterprise Value (EV) 2 555.9 1,940 2,620 1,642 1,377 1,767 1,761 1,697
P/E ratio -30 x -159 x 786 x 87.4 x 65.1 x 44.5 x 29.4 x 26.8 x
Yield - - - 0.57% 0.74% 0.58% 0.58% 0.58%
Capitalization / Revenue 5.96 x 15.6 x 15.7 x 6.61 x 4.49 x 5.12 x 4.4 x 3.6 x
EV / Revenue 5.96 x 15.6 x 15.8 x 6.59 x 4.85 x 5.44 x 4.66 x 3.67 x
EV / EBITDA - -408 x 131 x 46.3 x 24.4 x 26.3 x 18.6 x 15 x
EV / FCF - -51.1 x -58.9 x -30.7 x -32.8 x -301 x 76.1 x 52 x
FCF Yield - -1.96% -1.7% -3.25% -3.05% -0.33% 1.31% 1.92%
Price to Book - 6.56 x 8.11 x 4.88 x 3.32 x 3.91 x 3.6 x 3.14 x
Nbr of stocks (in thousands) 18,656 18,656 18,656 18,809 18,809 19,464 - -
Reference price 3 29,800 1,03,800 1,39,200 87,600 67,800 85,500 85,500 85,500
Announcement Date 13/03/20 19/02/21 24/02/22 16/02/23 01/02/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 93.26 124.2 165.6 249.3 284.1 324.9 378.3 462.2
EBITDA 1 - -4.749 19.99 35.45 56.54 67.25 94.49 112.8
EBIT 1 - -18.84 5.578 18.84 33.44 43.58 68.7 88.47
Operating Margin - -15.17% 3.37% 7.56% 11.77% 13.41% 18.16% 19.14%
Earnings before Tax (EBT) 1 - -16.84 7.965 20.22 23.35 42.86 64.71 69.75
Net income 1 - -12.15 4.712 18.85 17.52 35.14 53.6 58.65
Net margin - -9.78% 2.84% 7.56% 6.17% 10.82% 14.17% 12.69%
EPS 2 -993.0 -651.0 177.0 1,002 1,041 1,920 2,909 3,196
Free Cash Flow 3 - -37,924 -44,522 -53,448 -41,946 -5,860 23,143 32,650
FCF margin - -30,545.7% -26,878.72% -21,437.21% -14,764.26% -1,803.83% 6,117.3% 7,064.02%
FCF Conversion (EBITDA) - - - - - - 24,492.14% 28,944.5%
FCF Conversion (Net income) - - - - - - 43,176.97% 55,669.22%
Dividend per Share 2 - - - 500.0 500.0 500.0 500.0 500.0
Announcement Date 13/03/20 19/02/21 24/02/22 16/02/23 01/02/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 51.73 36.98 51.12 60.82 100.4 50.64 57.77 55.95 119.7 51.72 63.38 68.73 136.5 65.8 88.3
EBITDA 1 - - - 8.659 16.12 8.95 6.927 - - 7.892 13.9 15.6 23.7 - -
EBIT 1 -0.564 0.537 3.535 4.542 10.23 3.709 1.608 6.669 21.45 1.879 5.05 7.867 28.77 9.3 10.1
Operating Margin -1.09% 1.45% 6.91% 7.47% 10.19% 7.32% 2.78% 11.92% 17.91% 3.63% 7.97% 11.45% 21.07% 14.13% 11.44%
Earnings before Tax (EBT) 1 -4.91 -0.218 4.641 11.89 3.916 - 0.994 5.099 12.29 7.508 4.8 6.1 32.1 10.3 11.1
Net income 1 -3.126 1.907 3.403 10.2 3.341 3.788 1.332 3.931 9.426 6.234 4.067 4.7 25 8 8.6
Net margin -6.04% 5.16% 6.66% 16.76% 3.33% 7.48% 2.31% 7.03% 7.87% 12.05% 6.42% 6.84% 18.31% 12.16% 9.74%
EPS - - - - - 201.0 - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 24/02/22 28/04/22 08/08/22 31/10/22 16/02/23 28/04/23 27/07/23 31/10/23 01/02/24 02/05/24 - - - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 3.02 23.2 - 102 103 97.2 33.2
Net Cash position 1 - - - 5.2 - - - -
Leverage (Debt/EBITDA) - -0.636 x 1.163 x - 1.804 x 1.524 x 1.029 x 0.2946 x
Free Cash Flow 2 - -37,924 -44,522 -53,448 -41,946 -5,860 23,143 32,650
ROE (net income / shareholders' equity) - -4.67% 1.55% 5.55% 4.81% 9.18% 12.7% 14.4%
ROA (Net income/ Total Assets) - -3.56% 0.7% 3.53% 3.14% 5.08% 7.41% 9.02%
Assets 1 - 340.8 671.6 534.6 557.5 691.5 723.7 650
Book Value Per Share 3 - 15,830 17,171 17,951 20,445 21,871 23,780 27,231
Cash Flow per Share 3 - - 389.0 374.0 69.00 2,901 4,862 5,550
Capex 1 - 17 51.8 60.5 43.2 49.9 40.7 9.08
Capex / Sales - 13.68% 31.27% 24.26% 15.22% 15.36% 10.76% 1.96%
Announcement Date 13/03/20 19/02/21 24/02/22 16/02/23 01/02/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for ST Pharm Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
85,500 KRW
Average target price
1,11,333 KRW
Spread / Average Target
+30.21%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ST PHARM CO.,LTD. Stock ST Pharm Co.,Ltd.
+26.11% 1.21B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 815B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.05% 641B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
NOVARTIS AG Stock Novartis AG
+13.31% 218B
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
PFIZER, INC. Stock Pfizer, Inc.
-2.81% 159B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A237690 Stock
  4. Financials ST Pharm Co.,Ltd.